Table 2.

Change of management due to rapid MRI protocol or TRUS biopsy

	Management changed by MRI
Diagnosis on targeted biopsy	Diagnosis on TRUS biopsy	N (%)
Gleason 3+4	Benign prostatic tissue	8 (6.2%)
Gleason 3+4	Gleason 3+3	2 (1.6%)
Gleason 4+3	Gleason 3+3	2 (1.6%)
Gleason 4+3	Benign prostatic tissue	1 (0.8%)
Gleason 4+4	Benign prostatic tissue	1 (0.8%)
Gleason 4+4	Gleason 4+3	1 0.8(%)
	Management changed by 12-quadrant TRUS biopsy
Diagnosis on targeted biopsy	Diagnosis on TRUS biopsy	N
No suspicious lesion to target	Gleason 3+4	2 (1.6%)
No suspicious lesion to target	Gleason 4+3	1 (0.8%)
Gleason 3+3	Gleason 3+4	1 (0.8%)
Gleason 3+3	Gleason 4+3	1 (0.8%)
Gleason 3+4	Gleason 4+3	2 (1.6%)
Gleason 4+3	Gleason 4+4	1 (0.8%)
Gleason 5+4	Gleason 5+5	1 (0.8%)

In 15 out of 129 (%) patients targeted biopsy based on findings from the rapid biparametric MRI protocol revealed an increase of histological tumor grade compared to the diagnosis based on TRUS biopsy. In 3 out of 129 (2.3%) patients there was no targetable lesion identifiable on MRI Images although TRUS biopsy diagnosed a Gleason 3+4 (n=2) and 4+3 (n=1) cancer. In 6 out of 129 (4.7%) histological tumor grade increased from targeted to TRUS biopsy. However, diagnosis changed from clinically insignificant to significant cancer in 2 patients (1.6%).

MRI = Magnetic resonance imaging, TRUS = Transrectal ultrasound